Orphanet: An Open label, Multi center, Phase I IbII Study of AUY922 Administered as Single Agent and in Combination With Bortezomib With or Without Dexamethasone in Adult Patients in Relapse or Refractory Multiple Myeloma coordination
x

Search for a networks

* (*) mandatory field

An Open-label, Multi-center, Phase I-Ib/II Study of AUY922 Administered as Single Agent and in Combination With Bortezomib With or Without Dexamethasone in Adult Patients in Relapse or Refractory Multiple Myeloma (coordination)

  • Type of network : Multinational clinical trials
  • Geographic coverage : Global
  • Funding body(ies) : -
  • Sponsor : Novartis pharma services ag
  • Website
Last update: April 2011

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.